Research & Development

The pharmaceutical industry is currently facing a transformative and deeply sobering moment in immunology following the sudden, high-profile termination of a once-promising clinical drug program. For years, the OX40 receptor—a potent costimulatory molecule on T-cells—was hailed as the next frontier

Ivan Kairatov is a distinguished biopharma expert with a career built on navigating the intricate crossroads of biotechnology innovation and regulatory strategy. With extensive experience in research and development, he has spent years analyzing how emerging therapies transition from the laboratory

Ivan Kairatov is a biopharma expert with a profound understanding of industrial food engineering and its parallels with pharmacological addiction. With an extensive background in research and development, he has spent years analyzing how technological innovations in the food industry impact human

The precision of oncological surgery has long been tethered to the visual limitations of the human eye and the relative imprecision of conventional chemical markers. Traditional surgical imaging often fails to distinguish between microscopic malignant tissues and healthy cells, resulting in either

The biotechnology sector often operates on a knife-edge where a single clinical observation can evaporate years of progress and hundreds of millions of dollars in venture capital overnight. Aardvark Therapeutics recently experienced this volatility firsthand when it announced a voluntary suspension

Navigating the High Stakes of Roche’s Latest MS Breakthrough The pharmaceutical industry currently watches with bated breath as Roche’s fenebrutinib, a drug once hailed as the potential gold standard for oral multiple sclerosis (MS) therapy, hits a wall of regulatory uncertainty. While the clinical